This is a preview of subscription content, log in via an institution to check access.
Reference
Borse RH, et al. The Cost-Effectiveness of Golimumab as an Add-on to Conventional Care Compared to Cc for the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland. 17th Annual Congress of the European League Against Rheumatism : abstr. THU0629, 8 Jun 2016. Available from: URL: http://www.abstracts2view.com/eular/view.php?nu=EULAR16L_THU0629
Rights and permissions
About this article
Cite this article
Add-on golimumab cost effective for spondyloarthritis in Scotland. PharmacoEcon Outcomes News 758, 9 (2016). https://doi.org/10.1007/s40274-016-3238-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3238-3